D-0330-2021 Class III Ongoing

Recalled by Asclemed USA Inc. Dba Enovachem Pharmaceuticals — Torrance, CA

FDA drug recall D-0330-2021 was initiated by Asclemed USA Inc. Dba Enovachem Pharmaceuticals on Mar 19, 2021 and is designated Class III. Reason for recall: Labeling: Illegible label: Manufacturer received complaint of mis-alignment print of the printed dosing instructions on the blister card. The recall status is ongoing.

Recall details

Product Type
Drugs
Report Date
Apr 21, 2021
Initiation Date
Mar 19, 2021
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Distributed by: DocRx, Methylprednisolone Tablets, USP 4 mg, Rx, 21 Count Blister, NDC: 69306-004-21, Relabeled by: Enovachem Pharmaceuticals 379 Van Ness Ave. Suite 1403-1406, Torrance, CA 90501, Manufactured by: Jubilant Cadista Pharmaceuticals Inc. Source NDC: 59746-001-03, DocRx, Mobile, AL 36608

Reason for recall

Labeling: Illegible label: Manufacturer received complaint of mis-alignment print of the printed dosing instructions on the blister card.

Distribution pattern

Distributed to three physicians in the following states: CA, LA (Enovachem). DocRx distributed recalled product to one Distributor located in AL.

Code information

Lot #: 20K0043P, Exp. 8/31/2022; 20L0026P, Exp. 9/30/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0330-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0330-2021. Report a data issue: hello@regdatalab.com.